2022 ICIS 7th Expert Meeting on "Chronic Refractory ITP: Characterization, Definition, and Management in Children and Adults"

Dear Colleagues, 

The Intercontinental Cooperative ITP Study Group (ICIS, www.itpbasel.ch) is an academic organization, founded in 1997 by physicians to prospectively analyze the heterogeneous diagnostic and therapeutic aspects of immune thrombocytopenia (ITP). ICIS promotes international collaboration by collecting and evaluating long-term data of patients with ITP with a focus on diagnostic aspects and therapeutic options in ITP. ICIS organizes regular expert meetings in the field of pathophysiology, laboratory issues of the autoimmune disorder and immune-hematology.  Results, opinions, and reviews are published regularly. The goals of the chosen themes are clearly innovative, provocative, and future oriented. As an example, at the 3rd meeting in Switzerland, the results of a large number of registered follow-up data of patients induced an impulse for consensus activities in order to change the standardizations of the definitions of ITP (see Rodeghiero F et al, Blood 2009). ICIS publications are presented on its website (www.itpbasel.ch). One of the ongoing ICIS projects, the Pediatric and Adult Registry on chronic ITP (PARC-ITP), contains data of more than 4600 patients with follow-up data of 10 years after diagnosis from 36 countries, 97 institutions, and 114 investigators.

In 2022, ICIS is planning its 7th Expert Meeting in Switzerland by inviting 30–40 distinguished experts who will serve as chairpersons, speakers, and discussants in the meeting. These experts are involved in patient care, management, and laboratory research. The invitees to all expert meetings always travel by their own, and as a tradition, a small Swiss location is chosen to have a meeting with a stimulating atmosphere. This time, the meeting title will be “Chronic refractory ITP: Characterization, definition and management in children and adults”. After the meeting, each participant is invited to submit a manuscript for publication in a Special Issue of the journal Medicina.

Prof. Dr. Paul Imbach
Prof. Dr. Thomas Kühne
Dr. Alexandra Schifferli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• heterogeneity
• therapeutic approaches
• prediction if chronic
• refractory immune thrombocytopenia